Synthesis of rat parathymosin alpha fragment 1-28 and examination of its inhibitory activity towards the restoring activity of thymosin alpha 1 on the impaired T-lymphocytes of uremic patients.
Abiko. T T; Sekino. H H
Key Findings
- The synthetic parathymosin 1‑28 fragment showed no ability to restore function in impaired T‑lymphocytes.
- When combined with thymosin‑alpha‑1, the fragment suppressed thymosin‑alpha‑1’s immune‑restoring activity.
- The study used cells from uremic (kidney‑failure) patients, a specific disease context.
Practical Outcomes
- For DIY health enthusiasts using thymosin‑alpha‑1, adding or co‑administering parathymosin‑derived fragments could negate its immune‑boosting benefits. Until more data are available, avoid combining these peptides, especially in contexts of immune compromise. The finding mainly serves as a caution about potential antagonistic interactions rather than a new protocol.
Summary
Scientists made a short piece of a rat protein called parathymosin (the first 28 amino acids) and tested it on weak immune cells from kidney‑failure patients. By itself it did nothing, and when mixed with the immune‑boosting peptide thymosin‑alpha‑1 it actually blocked thymosin‑alpha‑1’s beneficial effect.
Abstract
A fragment corresponding to N-terminal octaeicosapeptide of rat parathymosin alpha was synthesized by assembling 5 peptide fragments, followed by deprotection with 1 M trifluoromethanesulfonic acid-thioanisole (molar ratio 1:1) in trifluoroacetic acid in the presence of dimethylselenium. Incubation of impaired T-lymphocytes isolated from uremic patients with the synthetic parathymosin alpha fragment 1-28 showed no immunological restoring effect, but when it was administered together with thymosin alpha 1, it appeared to suppress the restoring effect of the thymosin alpha 1 on the impaired T-lymphocytes of uremic patients.
Study Information
pubmed
1991
10.1248/cpb.39.2647